| scholarly article | Q13442814 |
| P50 | author | Chengcao Sun | Q86543265 |
| P2093 | author name string | Dejia Li | |
| Shujun Li | |||
| P2860 | cites work | A major inducer of anticarcinogenic protective enzymes from broccoli: isolation and elucidation of structure | Q24562666 |
| Cellular and molecular mechanisms of fibrosis | Q24648892 | ||
| Perspectives of stem cell therapy in Duchenne muscular dystrophy | Q27013613 | ||
| Recent progress in satellite cell/myoblast engraftment -- relevance for therapy | Q27014183 | ||
| Transforming growth factor beta in tissue fibrosis | Q28239292 | ||
| Gene and cell-mediated therapies for muscular dystrophy. | Q33831193 | ||
| Long-term blocking of calcium channels in mdx mice results in differential effects on heart and skeletal muscle | Q34469185 | ||
| Angiotensin II type 1 receptor blockade attenuates TGF-beta-induced failure of muscle regeneration in multiple myopathic states | Q35110459 | ||
| Common and unique mechanisms regulate fibrosis in various fibroproliferative diseases | Q35649473 | ||
| PAI-1-regulated miR-21 defines a novel age-associated fibrogenic pathway in muscular dystrophy. | Q35666298 | ||
| Expression of transforming growth factor-beta 1 in dystrophic patient muscles correlates with fibrosis. Pathogenetic role of a fibrogenic cytokine. | Q35753459 | ||
| Sulforaphane Attenuates Muscle Inflammation in Dystrophin-deficient mdx Mice via NF-E2-related Factor 2 (Nrf2)-mediated Inhibition of NF-κB Signaling Pathway | Q35859481 | ||
| Inhibition of muscle fibrosis results in increases in both utrophin levels and the number of revertant myofibers in Duchenne muscular dystrophy. | Q36414153 | ||
| The NRF2-heme oxygenase-1 system modulates cyclosporin A-induced epithelial-mesenchymal transition and renal fibrosis | Q36652097 | ||
| Molecular basis for chemoprevention by sulforaphane: a comprehensive review. | Q36775326 | ||
| Emerging role of Nrf2 in protecting against hepatic and gastrointestinal disease | Q36846919 | ||
| Pathobiology of transforming growth factor beta in cancer, fibrosis and immunologic disease, and therapeutic considerations | Q36921222 | ||
| Transforming growth factor-beta and myostatin signaling in skeletal muscle | Q37011013 | ||
| Therapeutic advances in muscular dystrophy | Q37455625 | ||
| Targeting fibrosis in Duchenne muscular dystrophy | Q37770947 | ||
| The Nrf2 system as a potential target for the development of indirect antioxidants. | Q37802176 | ||
| Repair or replace? Exploiting novel gene and cell therapy strategies for muscular dystrophies | Q38079633 | ||
| Pharmacological prospects in the treatment of Duchenne muscular dystrophy | Q38133306 | ||
| Sulforaphane attenuates hepatic fibrosis via NF-E2-related factor 2-mediated inhibition of transforming growth factor-β/Smad signaling | Q39431057 | ||
| Resveratrol ameliorates muscular pathology in the dystrophic mdx mouse, a model for Duchenne muscular dystrophy. | Q39528770 | ||
| Prevention of muscle fibrosis and improvement in muscle performance in the mdx mouse by halofuginone | Q39955104 | ||
| Fibrinogen drives dystrophic muscle fibrosis via a TGFbeta/alternative macrophage activation pathway | Q41298517 | ||
| PGC-1 alpha regulates expression of myocardial mitochondrial antioxidants and myocardial oxidative stress after chronic systolic overload | Q42406946 | ||
| Localization and early time course of TGF-beta 1 mRNA expression in dystrophic muscle | Q45076412 | ||
| Functional resolution of fibrosis in mdx mouse dystrophic heart and skeletal muscle by halofuginone | Q46761904 | ||
| Temporal and spatial mRNA expression patterns of TGF-beta1, 2, 3 and TbetaRI, II, III in skeletal muscles of mdx mice. | Q54625653 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 377-390 | |
| P577 | publication date | 2015-10-22 | |
| P1433 | published in | Journal of Applied Physiology | Q1091719 |
| P1476 | title | Sulforaphane mitigates muscle fibrosis in mdx mice via Nrf2-mediated inhibition of TGF-β/Smad signaling. | |
| P478 | volume | 120 |
| Q37392616 | Hsa-miR-134 suppresses non-small cell lung cancer (NSCLC) development through down-regulation of CCND1. |
| Q36946799 | Hsa-miR-326 targets CCND1 and inhibits non-small cell lung cancer development. |
| Q37225326 | Hsa-miR-329 exerts tumor suppressor function through down-regulation of MET in non-small cell lung cancer |
| Q37520511 | Hsa-miR-875-5p exerts tumor suppressor function through down-regulation of EGFR in colorectal carcinoma (CRC) |
| Q61806444 | Identification of qPCR reference genes suitable for normalizing gene expression in the mdx mouse model of Duchenne muscular dystrophy |
| Q59334918 | Identifying chondroprotective diet-derived bioactives and investigating their synergism |
| Q33591426 | Imidazoline I2 receptor inhibitor idazoxan regulates the progression of hepatic fibrosis via Akt-Nrf2-Smad2/3 signaling pathway |
| Q58580808 | Inhibitory Effects of Momordicine I on High-Glucose-Induced Cell Proliferation and Collagen Synthesis in Rat Cardiac Fibroblasts |
| Q37501589 | Long Intergenic Noncoding RNA 00511 Acts as an Oncogene in Non-small-cell Lung Cancer by Binding to EZH2 and Suppressing p57. |
| Q42314770 | Long intergenic non-protein coding RNA 00858 functions as a competing endogenous RNA for miR-422a to facilitate the cell growth in non-small cell lung cancer |
| Q37530948 | Long non-coding RNA EWSAT1 promotes human nasopharyngeal carcinoma cell growth in vitro by targeting miR-326/-330-5p |
| Q41910784 | Long non-coding RNA LOC100129148 functions as an oncogene in human nasopharyngeal carcinoma by targeting miR-539-5p |
| Q37588369 | Long non-coding RNA NEAT1 promotes non-small cell lung cancer progression through regulation of miR-377-3p-E2F3 pathway. |
| Q37482545 | MicroRNA-1275 suppresses cell growth, and retards G1/S transition in human nasopharyngeal carcinoma by down-regulation of HOXB5. |
| Q37423551 | MicroRNA-346 facilitates cell growth and metastasis, and suppresses cell apoptosis in human non-small cell lung cancer by regulation of XPC/ERK/Snail/E-cadherin pathway. |
| Q42374210 | Nuclear factor (erythroid derived 2)-like 2 activation increases exercise endurance capacity via redox modulation in skeletal muscles |
| Q64965427 | Role of Transforming Growth Factor-β in Skeletal Muscle Fibrosis: A Review. |
| Q91858392 | The FRiND Model: A Mathematical Model for Representing Macrophage Plasticity in Muscular Dystrophy Pathogenesis |
| Q37501595 | The Novel miR-9600 Suppresses Tumor Progression and Promotes Paclitaxel Sensitivity in Non-small-cell Lung Cancer Through Altering STAT3 Expression |
| Q46675216 | The lncRNA PDIA3P Interacts with miR-185-5p to Modulate Oral Squamous Cell Carcinoma Progression by Targeting Cyclin D2. |
Search more.